About alemtuzumab
Anti-CD52 monoclonal antibody
Used for
- Treats relapsing forms of multiple sclerosis in selected adults with active disease.
Usual adult dose
12 mg by intravenous infusion daily for five days, then daily for three days one year later.
Common side effects
- Infusion reactions, including rash, fever, headache, or nausea
- Infections, including herpes infections
- Thyroid disorders
- Immune blood or kidney disorders
Important warnings
- Can cause serious autoimmune disorders; monitoring is required for at least 48 months after the last course.
- Serious infusion reactions and infections can occur.
- Rarely causes stroke, artery tears, or serious bleeding.
- Restricted distribution and specialist supervision are required.
Pregnancy
May harm an unborn baby; pregnancy status should be checked before treatment. Avoid pregnancy during treatment and for four months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for four months after the last dose.
Interactions
- Live vaccines should be avoided during treatment and until immune recovery.
- Other immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.